A Phase 3 interventional study of Tedizolid phosphate and Comparator in Acute Bacterial Skin and Skin Structure Infections, sponsored by Merck Sharp & Dohme LLC. Completed at 58 sites in 14 countries. Open to participants aged 1 Day to 11 Years. Per ClinicalTrials.gov, last updated 2025-07-31.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the safety, tolerability, and efficacy of tedizolid phosphate (MK-1986) compared with comparator antibacterial agent in participants from birth to less than 12 years of age with acute bacterial skin and skin structure infections (ABSSSI).
Participants will be randomized (3:1) to receive tedizolid phosphate at a weight-based dose ≤200 mg/day, intravenous (IV) and/or oral suspension for 6 to 10 days, or comparator IV and/or oral per local standard of care for 10 to 14 days. The switch from IV to oral administration can be made at any time based on 1) no worsening of the primary skin lesion, 2) last temperature \<37.7 °C, and 3) primary acute bacterial skin and skin structure infection (ABSSSI) site has not worsened and at least 1 site has improved from Baseline. The potential 4-day treatment extension will be based on clinical need as judged by the investigator, considering the following criteria: 1) ≥40% reduction in primary lesion size, 2) reduction in pain, and 3) no new signs and symptoms and no complications attributable to ABSSSI compared with Baseline.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to \<50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to \<30 kg), by IV and/or oral suspension for 6 to 10 days.
Drug: Tedizolid phosphate
Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days.
Drug: Comparator
Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to \<50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to \<30 kg), by IV and/or oral suspension for 6 to 10 days.
Drug: Tedizolid phosphate
Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days.
Drug: Comparator
Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to \<50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to \<30 kg), by IV and/or oral suspension for 6 to 10 days.
Drug: Tedizolid phosphate
Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days.
Drug: Comparator
Participants will receive tedizolid phosphate ≤200 mg daily dose, IV and/or oral suspension for 6 to 10 days. Exact mg/kg dose is to be determined based on results of another study (NCT03217565) covering the age range.
Drug: Tedizolid phosphate
Participants will receive comparator IV and/or oral per local standard of care for 10 to14 days.
Drug: Comparator
Tedizolid phosphate IV solution or oral suspension
Also known as: MK-1986, TR-701 FA
Vancomycin IV, linezolid IV or oral (outside European Union only), clindamycin IV or oral, flucloxacillin IV or oral, cefazolin IV, or cephalexin oral provided locally by the trial site and administered per local standard of care
Number of Participants Who Experienced an Adverse Event (AE)
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Number of participants who experienced an AE were reported.
Time frame: Up to approximately 35 days
Number of Participants Who Discontinued Study Treatment Due to an AE
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Number of participants who experienced an AE were reported. The number of participants who discontinued study treatment due to an AE were reported.
Time frame: Up to approximately day 15
Number of Participants With Hematopoietic Cytopenias
Hematopoietic cytopenia is a condition where there is a lower-than-normal amount of one or multiple kinds of blood cells. A standardized Medical Dictionary for Regulatory Activities (MedDRA) query for hematopoietic cytopenia was conducted. The number of participants with a hematopoietic cytopenia were reported.
Time frame: Up to approximately 35 days
Percentage of Participants With Clinical Response (CR) Per Investigator Assessment
CR was defined as clinical success, failure or indeterminate as per investigator assessment. Success was all of the following: resolution/near resolution of most disease-specific signs \& symptoms, absence/near resolution of regional/systemic signs of infection if present at baseline (BL) \& no new signs, symptoms, or complications, so, no further antibiotic therapy required. Failure was any of the following: requires additional antibiotic therapy, unplanned major surgical intervention required due to study drug failure, developed osteomyelitis after BL, persistent gram+ bacteremia, treatment emergent adverse event (TEAE) leading to study drug discontinuation \& required additional antibiotic therapy to treat infection or death within 28 days of first infusion. Indeterminate was no efficacy data available. Per protocol, percentage of participants with CR for Cohorts 1, 2 \& 3 \& all cohorts together were reported, \& failure \& indeterminate responses were pooled.
Time frame: Up to approximately 25 days
Percentage of Clinically Evaluable (CE) Participants With CR Per Investigator Assessment
CR was defined as clinical success, failure or indeterminate as per investigator assessment. Success was all of the following: resolution/near resolution of most disease-specific signs \& symptoms, absence/near resolution of regional/systemic signs of infection if present at BL \& no new signs, symptoms, or complications, so, no further antibiotic therapy required. Failure was any of the following: requires additional antibiotic therapy, unplanned major surgical intervention required due to study drug failure, developed osteomyelitis after BL, persistent gram+ bacteremia, treatment emergent adverse event leading to study drug discontinuation \& required additional antibiotic therapy to treat infection or death within 28 days of first infusion. Indeterminate was no efficacy data available. Per protocol, percentage of participants with CR for Cohorts 1, 2 \& 3 and all cohorts together were reported, \& failure \& indeterminate responses were pooled.
Time frame: Up to approximately 25 days
| Milestone | Cohort 1: Tedizolid Phosphate 6 to <12 Years | Cohort 1: Comparator 6 to <12 Years | Cohort 2: Tedizolid Phosphate 2 to <6 Years | Cohort 2: Comparator 2 to <6 Years | Cohort 3: Tedizolid Phosphate 28 Days to <2 Years | Cohort 3: Comparator 28 Days to <2 Years | Cohort 4: Tedizolid Phosphate Birth to <28 Days Term and Preterm Neonates | Cohort 4: Comparator Birth to <28 Days Term and Preterm Neonates |
|---|---|---|---|---|---|---|---|---|
| Started | 44 | 15 | 16 | 5 | 15 | 5 | 0 | 0 |
| Completed | 42 | 13 | 14 | 5 | 15 | 5 | 0 | 0 |
| Not completed | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by parent/guardian | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Number of participants who experienced an AE were reported.
| Participants | Cohort 1: Tedizolid Phosphate 6 to <12 Years | Cohort 1: Comparator 6 to <12 Years | Cohort 2: Tedizolid Phosphate 2 to <6 Years | Cohort 2: Comparator 2 to <6 Years | Cohort 3: Tedizolid Phosphate 28 Days to <2 Years | Cohort 3: Comparator 28 Days to <2 Years |
|---|---|---|---|---|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) | 7 | 2 | 7 | 2 | 7 | 2 |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Number of participants who experienced an AE were reported. The number of participants who discontinued study treatment due to an AE were reported.
| Participants | Cohort 1: Tedizolid Phosphate 6 to <12 Years | Cohort 1: Comparator 6 to <12 Years | Cohort 2: Tedizolid Phosphate 2 to <6 Years | Cohort 2: Comparator 2 to <6 Years | Cohort 3: Tedizolid Phosphate 28 Days to <2 Years | Cohort 3: Comparator 28 Days to <2 Years |
|---|---|---|---|---|---|---|
| Number of Participants Who Discontinued Study Treatment Due to an AE | 0 | 0 | 0 | 0 | 0 | 0 |
Hematopoietic cytopenia is a condition where there is a lower-than-normal amount of one or multiple kinds of blood cells. A standardized Medical Dictionary for Regulatory Activities (MedDRA) query for hematopoietic cytopenia was conducted. The number of participants with a hematopoietic cytopenia were reported.
| Participants | Cohort 1: Tedizolid Phosphate 6 to <12 Years | Cohort 1: Comparator 6 to <12 Years | Cohort 2: Tedizolid Phosphate 2 to <6 Years | Cohort 2: Comparator 2 to <6 Years | Cohort 3: Tedizolid Phosphate 28 Days to <2 Years | Cohort 3: Comparator 28 Days to <2 Years |
|---|---|---|---|---|---|---|
| Number of Participants With Hematopoietic Cytopenias | 0 | 0 | 1 | 0 | 1 | 0 |
CR was defined as clinical success, failure or indeterminate as per investigator assessment. Success was all of the following: resolution/near resolution of most disease-specific signs \& symptoms, absence/near resolution of regional/systemic signs of infection if present at baseline (BL) \& no new signs, symptoms, or complications, so, no further antibiotic therapy required. Failure was any of the following: requires additional antibiotic therapy, unplanned major surgical intervention required due to study drug failure, developed osteomyelitis after BL, persistent gram+ bacteremia, treatment emergent adverse event (TEAE) leading to study drug discontinuation \& required additional antibiotic therapy to treat infection or death within 28 days of first infusion. Indeterminate was no efficacy data available. Per protocol, percentage of participants with CR for Cohorts 1, 2 \& 3 \& all cohorts together were reported, \& failure \& indeterminate responses were pooled.
| Percentage of Participants | Cohort 1: Tedizolid Phosphate 6 to <12 Years | Cohort 1: Comparator 6 to <12 Years | Cohort 2: Tedizolid Phosphate 2 to <6 Years | Cohort 2: Comparator 2 to <6 Years | Cohort 3: Tedizolid Phosphate 28 Days to <2 Years | Cohort 3: Comparator 28 Days to <2 Years | All Cohorts: Tedizolid Phosphate | All Cohorts: Comparator |
|---|---|---|---|---|---|---|---|---|
| Clinical Success | 93.2 (81.3 to 98.6) | 86.7 (59.5 to 98.3) | 87.5 (61.7 to 98.4) | 100.00 (47.8 to 100.0) | 100.0 (78.2 to 100.0) | 100.0 (47.8 to 100.0) | 93.3 (85.1 to 97.8) | 92.0 (74.0 to 99.0) |
| Clinical Failure or Indeterminate | 6.8 (1.4 to 18.7) | 13.3 (1.7 to 40.5) | 12.5 (1.6 to 38.3) | 0.0 (NA to NA) | 0.0 (NA to NA) | 0.0 (NA to NA) | 6.7 (2.2 to 14.9) | 8.0 (1.0 to 26.0) |
CR was defined as clinical success, failure or indeterminate as per investigator assessment. Success was all of the following: resolution/near resolution of most disease-specific signs \& symptoms, absence/near resolution of regional/systemic signs of infection if present at BL \& no new signs, symptoms, or complications, so, no further antibiotic therapy required. Failure was any of the following: requires additional antibiotic therapy, unplanned major surgical intervention required due to study drug failure, developed osteomyelitis after BL, persistent gram+ bacteremia, treatment emergent adverse event leading to study drug discontinuation \& required additional antibiotic therapy to treat infection or death within 28 days of first infusion. Indeterminate was no efficacy data available. Per protocol, percentage of participants with CR for Cohorts 1, 2 \& 3 and all cohorts together were reported, \& failure \& indeterminate responses were pooled.
| Percentage of Participants | Cohort 1: Tedizolid Phosphate 6 to <12 Years | Cohort 1: Comparator 6 to <12 Years | Cohort 2: Tedizolid Phosphate 2 to <6 Years | Cohort 2: Comparator 2 to <6 Years | Cohort 3: Tedizolid Phosphate 28 Days to <2 Years | Cohort 3: Comparator 28 Days to <2 Years | All Cohorts: Tedizolid Phosphate | All Cohorts: Comparator |
|---|---|---|---|---|---|---|---|---|
| Clinical Success | 100.00 (91.0 to 100.0) | 100.0 (75.3 to 100.0) | 100.0 (76.8 to 100.0) | 100.00 (47.8 to 100.0) | 100.0 (78.2 to 100.0) | 100.0 (47.8 to 100.0) | 100.00 (94.7 to 100.0) | 100.0 (85.2 to 100.0) |
| Clinical Failure or Indeterminate | 0.0 (NA to NA) | 0.0 (NA to NA) | 0.0 (NA to NA) | 0.0 (NA to NA) | 0.0 (NA to NA) | 0.0 (NA to NA) | 0.0 (NA to NA) | 0.0 (NA to NA) |
Collected over Up to approximately 35 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Tedizolid Phosphate 6 to <12 Years | 0/44 (0%) | 0/44 (0%) | 4/44 (9.1%) |
| Cohort 1: Comparator 6 to <12 Years | 0/15 (0%) | 0/15 (0%) | 2/15 (13.3%) |
| Cohort 2: Tedizolid Phosphate 2 to <6 Years | 0/16 (0%) | 0/16 (0%) | 7/16 (43.8%) |
| Cohort 2: Comparator 2 to <6 Years | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| Cohort 3: Tedizolid Phosphate 28 Days to <2 Years | 0/15 (0%) | 0/15 (0%) | 7/15 (46.7%) |
| Cohort 3: Comparator 28 Days to <2 Years | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| Event | Cohort 1: Tedizolid Phosphate 6 to <12 Years | Cohort 1: Comparator 6 to <12 Years | Cohort 2: Tedizolid Phosphate 2 to <6 Years | Cohort 2: Comparator 2 to <6 Years | Cohort 3: Tedizolid Phosphate 28 Days to <2 Years | Cohort 3: Comparator 28 Days to <2 Years |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 1/44 | 0/15 | 0/16 | 1/5 | 0/15 | 2/5 |
| ConstipationGastrointestinal disorders | 0/44 | 0/15 | 0/16 | 1/5 | 0/15 | 0/5 |
| FolliculitisInfections and infestations | 0/44 | 0/15 | 0/16 | 0/5 | 3/15 | 0/5 |
| Upper respiratory tract infectionInfections and infestations | 0/44 | 0/15 | 0/16 | 1/5 | 2/15 | 0/5 |
| Thermal burnInjury, poisoning and procedural complications | 0/44 | 0/15 | 0/16 | 1/5 | 0/15 | 0/5 |
| Aspartate aminotransferase increasedInvestigations | 0/44 | 0/15 | 1/16 | 1/5 | 0/15 | 0/5 |
| Decreased appetiteMetabolism and nutrition disorders | 0/44 | 0/15 | 0/16 | 1/5 | 1/15 | 1/5 |
| AlopeciaSkin and subcutaneous tissue disorders | 0/44 | 0/15 | 0/16 | 1/5 | 0/15 | 0/5 |
| Dermatitis diaperSkin and subcutaneous tissue disorders | 0/44 | 0/15 | 0/16 | 0/5 | 1/15 | 1/5 |
| MiliariaSkin and subcutaneous tissue disorders | 0/44 | 0/15 | 0/16 | 0/5 | 0/15 | 1/5 |
All randomized participants.
| Age, Continuous(years) | Cohort 1: Tedizolid Phosphate 6 to <12 Years | Cohort 1: Comparator 6 to <12 Years | Cohort 2: Tedizolid Phosphate 2 to <6 Years | Cohort 2: Comparator 2 to <6 Years | Cohort 3: Tedizolid Phosphate 28 Days to <2 Years | Cohort 3: Comparator 28 Days to <2 Years | Total |
|---|---|---|---|---|---|---|---|
| Mean | 8.5 ± 1.7 | 9.2 ± 1.4 | 3.1 ± 1.1 | 3.4 ± 1.1 | 0.9 ± 0.2 | 1.0 ± 0.1 | 6.0 ± 3.6 |
| Sex: Female, Male(Participants) | Cohort 1: Tedizolid Phosphate 6 to <12 Years | Cohort 1: Comparator 6 to <12 Years | Cohort 2: Tedizolid Phosphate 2 to <6 Years | Cohort 2: Comparator 2 to <6 Years | Cohort 3: Tedizolid Phosphate 28 Days to <2 Years | Cohort 3: Comparator 28 Days to <2 Years | Total |
|---|---|---|---|---|---|---|---|
| Female | 16 | 8 | 8 | 2 | 11 | 2 | 47 |
| Male | 28 | 7 | 8 | 3 | 4 | 3 | 53 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: Tedizolid Phosphate 6 to <12 Years | Cohort 1: Comparator 6 to <12 Years | Cohort 2: Tedizolid Phosphate 2 to <6 Years | Cohort 2: Comparator 2 to <6 Years | Cohort 3: Tedizolid Phosphate 28 Days to <2 Years | Cohort 3: Comparator 28 Days to <2 Years | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 2 | 5 | 1 | 2 | 1 | 17 |
| Not Hispanic or Latino | 38 | 13 | 11 | 4 | 13 | 4 | 83 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1: Tedizolid Phosphate 6 to <12 Years | Cohort 1: Comparator 6 to <12 Years | Cohort 2: Tedizolid Phosphate 2 to <6 Years | Cohort 2: Comparator 2 to <6 Years | Cohort 3: Tedizolid Phosphate 28 Days to <2 Years | Cohort 3: Comparator 28 Days to <2 Years | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 0 | 9 | 1 | 11 |
| White | 41 | 15 | 13 | 4 | 4 | 3 | 80 |
| More than one race | 3 | 0 | 2 | 1 | 1 | 1 | 8 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jan 2019 to primary completion in Jul 2023, 53 months.
Results were first posted in Jul 2024, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tedizolid phosphate